文献速递浆细胞疾病造血干细胞移植与细胞治疗

抗G蛋白偶联受体C类第5组成员D嵌合抗原受体T细胞治疗复发或难治性多发性骨髓瘤:单臂Ⅱ期试验

Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial.
PubMed 文献 · J Clin Oncol · 2023-03-07

这项单臂Ⅱ期研究纳入33例复发或难治性多发性骨髓瘤患者,在淋巴细胞清除后输注2×10^6/kg抗GPRC5D CAR T细胞。中位随访5.2个月时总缓解率为91%(95%CI 76-98),9例既往接受过抗BCMA CAR T细胞治疗的患者均达到部分缓解或更好。≥3级血液学毒性包括中性粒细胞减少33例(100%)、贫血17例(52%)和血小板减少15例(45%),细胞因子释放综合征25例(76%)均为1-2级。

要点

  • 抗GPRC5D CAR T细胞在复发或难治性多发性骨髓瘤中总缓解率达91%(95%CI 76-98)。
  • 9例既往抗BCMA CAR T细胞治疗患者中9例(100%)达部分缓解或更好。
  • 细胞因子释放综合征发生25例(76%),均为1级或2级。

核心结论

  • 抗GPRC5D CAR T细胞治疗在复发或难治性多发性骨髓瘤患者中显示出令人鼓舞的临床疗效和可控的安全性。
  • 对于抗BCMA CAR T细胞治疗后进展或对抗BCMA CAR T细胞难治的多发性骨髓瘤患者,抗GPRC5D CAR T细胞治疗可能是一种潜在的替代选择。

研究设计与样本

  • 这是一项Ⅱ期单臂研究,纳入年龄18-70岁的复发或难治性多发性骨髓瘤患者。
  • 患者在淋巴细胞清除后接受2×10^6/kg抗GPRC5D CAR T细胞输注。
  • 主要终点为达到总体缓解的患者比例,同时对符合条件患者进行安全性评估。

主要发现

  • 2021年9月1日至2022年3月23日期间,共33例患者接受了抗GPRC5D CAR T细胞输注。
  • 中位随访5.2个月(范围3.2-8.9)时,总缓解率为91%(95%CI 76-98;33例中30例)。
  • 缓解包括11例(33%)严格完全缓解、10例(30%)完全缓解、4例(12%)非常好的部分缓解和5例(15%)部分缓解。
  • 9例既往接受过抗BCMA CAR T细胞治疗的患者中9例(100%)达到部分缓解或更好,包括2例既往重复接受抗BCMA CAR T细胞输注且末次无缓解的患者。
  • ≥3级血液学毒性包括中性粒细胞减少33例(100%)、贫血17例(52%)和血小板减少15例(45%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: G protein-coupled receptor, class C group 5 member D (GPRC5D) is considered to be a promising surface target for multiple myeloma (MM) immunotherapy. Here, we report the efficacy and safety of anti-GPRC5D chimeric antigen receptor (CAR) T cells in patients with relapsed or refractory (R/R) MM. METHODS: This phase Ⅱ, single-arm study enrolled patients (18-70 years) with R/R MM. Lymphodepletion was performed before patients received 2 × 106/kg anti-GPRC5D CAR T cells. The primary end point was the proportion of patients who achieved an overall response. Safety was also evaluated in eligible patients. RESULTS: From September 1, 2021, to March 23, 2022, 33 patients were infused with anti-GPRC5D CAR T cells. At a median follow-up of 5.2 months (range, 3.2-8.9), the overall response rate was 91% (95% CI, 76 to 98; 30 of 33 patients), including 11 (33%) stringent complete responses, 10 (30%) complete responses, four (12%) very good partial responses, and five (15%) partial responses. Partial responses or better were observed in nine (100%) of nine patients with previous anti-B-cell maturation antigen (BCMA) CAR T-cell therapy, including two patients who had received repeated anti-BCMA CAR T-cell infusions with no responses at the last time. Grade 3 or higher hematologic toxicities were neutropenia (33 [100%]), anemia (17 [52%]), and thrombocytopenia (15 [45%]). Cytokine release syndrome occurred in 25 (76%) of 33 patients (all were grade 1 or 2), and neurotoxicities in three patients (one grade 2 and one grade 3 ICANSs and one grade 3 headache). CONCLUSION: Anti-GPRC5D CAR T-cell therapy showed an encouraging clinical efficacy and manageable safety profile in patients with R/R MM. For patients with MM that progressed after anti-BCMA CAR T-cell therapy or that is refractory to anti-BCMA CAR T cell, anti-GPRC5D CAR T-cell therapy might be a potential alternative option.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Xia J, Li H, Yan Z, et al. Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial. J Clin Oncol. 2023. PMID: 36881785. doi:10.1200/JCO.22.01824

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。